COMPASS Pathways plc Earnings Recaps
Q2 2026
Aug 10, 2026
The stock surged 14.8% following the quarter, reflecting strong investor enthusiasm around COMPASS Pathways' highly statistically significant Phase III trial results for COMP360 and clear progress toward an NDA filing and launch readiness.
Key takeaways
- Reported positive Phase III primary endpoint results demonstrating rapid and durable efficacy in treatment-resistant depression (TRD).
- NDA rolling submission is underway with completion expected in Q4 2026 and potential for accelerated FDA approval.
- Robust cash position of $433 million supports operations through launch and into 2028.
- Commercial team fully built out with extensive launch experience; active preparations for sales force recruitment and market readiness.
- Plans to leverage existing interventional psychiatry infrastructure (8,000+ sites), facilitating a smoother market entry.
Q1 2026
May 14, 2026
The 17% stock rally signals strong investor approval of COMPASS Pathways’ progress toward NDA submission and potential accelerated launch of COMP360 for treatment-resistant depression (TRD), supported by positive Phase III data and regulatory milestones.
Key takeaways
- Confirmed rolling NDA submission underway with final data expected in early Q3, supporting potential approval later this year.
- Awarded the Commissioner's National Priority Voucher, enabling an ultra-accelerated FDA review timeline of 1-2 months post submission.
- Positive Phase III trial results affirm COMP360’s rapid onset and sustained efficacy for TRD, offering a differentiated profile from existing treatments.
- Commercial preparations progressing ahead of launch, including a growing salesforce and established psychedelic-specific CPT billing codes to facilitate reimbursement.
- Early-stage PTSD program advancing with site activations, expanding the potential addressable market beyond TRD.
Q3 2025
Nov 5, 2025
COMPASS Pathways reported significant progress in its Phase III trials for COMP360, with an accelerated NDA filing timeline now targeted for Q1 2026, positioning the company for potential market entry into treatment-resistant depression (TRD).
Key takeaways
- The completion of enrollment in the COMP006 trial enhances clarity for data readouts and regulatory timelines.
- Positive discussions with the FDA support a rolling NDA submission strategy and a potential accelerated launch.
- Cash reserves stand at $186 million, providing a runway into 2027, with disciplined spending amid ongoing operational expenditures.
- Ongoing preparations for commercial launch leverage insights from provider dynamics and patient preferences, aiming for effective integration into expanding psychiatric treatment infrastructure.